Chemed Corp. (CHE) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Chemed’s revenue went from $1.6B in fiscal 2016 to $2.5B in fiscal 2025, growth of about 5.4% a year.
Net income in fiscal 2025 was $265M, a net margin of 10.5%; the best year in this period was 2020 with $319M.
Over the twelve months to September 30, 2026, revenue was $2.7B and net income $282M.
Free cash flow was $325M in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 14% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.7B | $2.5B | $2.4B | $2.3B | $2.1B | $2.1B | $2.1B | $1.9B | $1.8B | $1.7B | $1.6B |
| Gross profit | $893M | $823M | $854M | $799M | $765M | $770M | $701M | $617M | $555M | $516M | $461M |
| Operating income | $371M | $338M | $366M | $341M | $343M | $343M | $390M | $257M | $244M | $113M | $179M |
| Net income | $282M | $265M | $302M | $273M | $250M | $269M | $319M | $220M | $206M | $98M | $109M |
| EPS (diluted) | $20.87 | $18.34 | $19.89 | $17.93 | $16.53 | $16.85 | $19.48 | $13.31 | $12.23 | $5.86 | $6.48 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +4.1% | +7.4% | +6.1% | −0.2% | +2.9% | +7.3% | +8.8% | +7.0% | +5.7% | +2.2% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $363M | $388M | $417M | $330M | $310M | $309M | $489M | $301M | $287M | $162M | $135M |
| Capital spending | -$68M | -$63M | -$50M | -$57M | -$57M | -$59M | -$59M | -$53M | -$53M | -$64M | -$40M |
| Free cash flow | $295M | $325M | $368M | $273M | $253M | $250M | $430M | $248M | $234M | $98M | $96M |
| Dividends paid | $34M | $32M | $27M | $24M | $22M | $22M | $21M | $20M | $19M | $17M | $16M |
| Buybacks | $525M | $432M | $361M | $68M | $115M | $576M | $176M | $93M | $159M | $95M | $102M |
| Stock-based pay | — | $39M | $52M | $41M | $34M | $31M | $27M | $21M | $19M | $16M | $14M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $75M | $178M | $264M | $74M | $33M | $163M | $6M | $5M | $11M | $15M |
| Debt | — | $144M | $141M | $139M | $247M | $324M | $135M | $216M | $89M | $101M | $109M |
| Equity | — | $979M | $1.1B | $1.1B | $799M | $623M | $901M | $727M | $591M | $540M | $524M |
| Total assets | — | $1.5B | $1.7B | $1.7B | $1.4B | $1.3B | $1.4B | $1.3B | $976M | $920M | $880M |
| Shares (diluted) | 13M | 14M | 15M | 15M | 15M | 16M | 16M | 17M | 17M | 17M | 17M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 33.5% | 32.5% | 35.1% | 35.3% | 35.8% | 36.0% | 33.7% | 31.9% | 31.1% | 31.0% | 29.3% |
| Operating margin | 13.9% | 13.4% | 15.1% | 15.0% | 16.1% | 16.0% | 18.7% | 13.3% | 13.7% | 6.8% | 11.3% |
| Net margin | 10.6% | 10.5% | 12.4% | 12.0% | 11.7% | 12.6% | 15.4% | 11.3% | 11.5% | 5.9% | 6.9% |
| FCF margin | 11.1% | 12.9% | 15.1% | 12.1% | 11.8% | 11.7% | 20.7% | 12.8% | 13.1% | 5.9% | 6.1% |
| ROIC | — | 22.4% | 22.0% | 21.2% | 24.9% | 27.8% | 30.3% | 23.0% | 30.7% | 14.8% | 17.3% |
| ROE | — | 27.1% | 27.0% | 24.6% | 31.2% | 43.1% | 35.4% | 30.3% | 34.8% | 18.2% | 20.8% |
Frequently asked questions
What is Chemed’s annual revenue?
$2.5B in fiscal 2025 and $2.7B over the twelve months to September 30, 2026.
How much profit does Chemed make?
Net income was $265M in fiscal 2025 (net margin 10.5%).
Is Chemed’s revenue growing?
Yes: revenue rose 4.1% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.